Baxter announces u.s. fda approval and launch of ready-to-use cardiovascular medicine norepinephrine in premix formulation

Deerfield, ill.--(business wire)--baxter announced the u.s. fda approval and commercial launch of premix norepinephrine bitartrate in 5% dextrose injection (norepinephrine).

BAX Ratings Summary

BAX Quant Ranking